Skip to main content
Top
Published in: Rheumatology International 1/2016

01-01-2016 | Original Article - Epidemiology of RMD

Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012

Authors: Matteo Piga, Laura Casula, Silvia Sanna, Daniela Perra, Alberto Floris, Antonello Antonelli, Alberto Cauli, Alessandro Mathieu

Published in: Rheumatology International | Issue 1/2016

Login to get access

Abstract

The aim of this study was to evaluate systemic sclerosis (SSc) hospitalizations through a retrospective population-based study analyzing administrative data during 2001–2012 in Sardinia, an Italian region with universal Health System coverage. Data on hospital discharge records with ICD-9-CM code for SSc (710.1) were obtained from the Department of Health and Hygiene. Two-tailed Cochran–Armitage test for trend was applied to analyze the annual trend for primary and non-primary discharge diagnoses. SSc prevalence was also estimated. This study included 4981 hospitalizations in 736 patients (84.8 % women). Hospitalizations with SSc as primary diagnosis were 3631 (72.9 %). Their annual number significantly increased during study period, from 143 in 2001 to 390 in 2012. Annual trend analysis revealed statistically significant increase in number and percentage of interstitial lung disease (p < 0.0001), pulmonary arterial hypertension (p < 0.0024), osteoporotic fragility fractures (p < 0.0001), ulcers, and gangrene (p = 0.0037) as non-primary diagnoses associated with SSc. Although the number of admissions with SSc as non-primary diagnosis showed a slight reduction during the study period, the annual number and percentage of admissions with respiratory failure (p = 0.0016) and congestive heart failure (p < 0.0001) as primary diagnosis showed a significant upward trend. Admissions for intravenous infusion, mainly day-hospital, accounted for 19.1 % of all hospitalizations for SSc and showed a significant (p = 0.0002) upward trend in 2001–2012. The 2012 SSc prevalence in Sardinia was estimated to be 34.8 per 100,000 inhabitants. Hospital care utilization for SSc is changing over time, showing increased hospitalizations aimed at the early recognition and treatment for the major manifestations and complications of SSc.
Appendix
Available only for authorised users
Literature
1.
go back to reference LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
2.
go back to reference Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef
3.
go back to reference Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 69:1809–1815PubMedCrossRef Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 69:1809–1815PubMedCrossRef
4.
go back to reference Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81:139–153CrossRef Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81:139–153CrossRef
6.
go back to reference Czirjak L, Kumanovics G, Varju C et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67:59–63PubMedCrossRef Czirjak L, Kumanovics G, Varju C et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67:59–63PubMedCrossRef
7.
go back to reference Karassa FB, Ioannidis JP (2008) Mortality in systemic sclerosis. Clin Exp Rheumatol 26:S85–S93PubMed Karassa FB, Ioannidis JP (2008) Mortality in systemic sclerosis. Clin Exp Rheumatol 26:S85–S93PubMed
8.
go back to reference Vacca A, Montisci R, Garau P et al (2013) Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests. Arthritis Res Ther 15:R8PubMedPubMedCentralCrossRef Vacca A, Montisci R, Garau P et al (2013) Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests. Arthritis Res Ther 15:R8PubMedPubMedCentralCrossRef
9.
go back to reference Chung L, Krishnan E, Chakravarty EF (2007) Hospitalizations and mortality in systemic sclerosis: results from the nationwide inpatient sample. Rheumatology (Oxford) 46:1808–1813CrossRef Chung L, Krishnan E, Chakravarty EF (2007) Hospitalizations and mortality in systemic sclerosis: results from the nationwide inpatient sample. Rheumatology (Oxford) 46:1808–1813CrossRef
10.
go back to reference Netwijitpan S, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2013) Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis. Clin Rheumatol 32:361–367PubMedCrossRef Netwijitpan S, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2013) Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis. Clin Rheumatol 32:361–367PubMedCrossRef
11.
go back to reference Barnabe C, Joseph L, Belisle P et al (2012) Prevalence of systemic lupus erythematosus and systemic sclerosis in the Firs Nations population of Alberta, Canada. Arthritis Care Res (Hoboken) 64:138–143CrossRef Barnabe C, Joseph L, Belisle P et al (2012) Prevalence of systemic lupus erythematosus and systemic sclerosis in the Firs Nations population of Alberta, Canada. Arthritis Care Res (Hoboken) 64:138–143CrossRef
12.
go back to reference Ward MM (2005) Estimating rare disease prevalence from administrative hospitalization databases. Epidemiology 16:270–271PubMedCrossRef Ward MM (2005) Estimating rare disease prevalence from administrative hospitalization databases. Epidemiology 16:270–271PubMedCrossRef
13.
go back to reference Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223–235PubMedCrossRef Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (2008) Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 37:223–235PubMedCrossRef
14.
go back to reference Allcock RS, Forrest I, Corris PA, Crook PR, Griffiths ID (2004) A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43:596–602PubMedCrossRef Allcock RS, Forrest I, Corris PA, Crook PR, Griffiths ID (2004) A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 43:596–602PubMedCrossRef
15.
go back to reference Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 61:400–404PubMedCrossRef Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 61:400–404PubMedCrossRef
16.
17.
go back to reference Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR et al (2008) Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore) 87:272–280CrossRef Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR et al (2008) Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore) 87:272–280CrossRef
20.
go back to reference Piga M, Casula L, Perra D et al (2015) Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with Systemic Lupus Erythematosus over the period 2001–2012. Lupus. doi:10.1177/0961203315596597 Piga M, Casula L, Perra D et al (2015) Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with Systemic Lupus Erythematosus over the period 2001–2012. Lupus. doi:10.​1177/​0961203315596597​
21.
go back to reference Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized controlled study. Clin Exp Rheumatol 19:503–508PubMed Scorza R, Caronni M, Mascagni B et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized controlled study. Clin Exp Rheumatol 19:503–508PubMed
22.
go back to reference Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19:1403–1406PubMed Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19:1403–1406PubMed
23.
go back to reference Bettoni L, Geri A, Airo P et al (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250PubMedCrossRef Bettoni L, Geri A, Airo P et al (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250PubMedCrossRef
24.
go back to reference Torley HI, Madhok R, Capell HA et al (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud’s phenomenon secondary to connective tissue disease. Ann Rheum Dis 50:800–804PubMedPubMedCentralCrossRef Torley HI, Madhok R, Capell HA et al (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud’s phenomenon secondary to connective tissue disease. Ann Rheum Dis 50:800–804PubMedPubMedCentralCrossRef
25.
go back to reference Oudiz RJ, Schilz RJ, Barst RJ et al (2004) Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420–427PubMedCrossRef Oudiz RJ, Schilz RJ, Barst RJ et al (2004) Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420–427PubMedCrossRef
26.
go back to reference Lefèvre G, Dauchet L, Hachulla E et al (2013) Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65:2412–2423PubMedCrossRef Lefèvre G, Dauchet L, Hachulla E et al (2013) Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65:2412–2423PubMedCrossRef
27.
go back to reference Gladue H, Altorok N, Townsend W, McLaughlin V, Khanna D (2014) Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 43:536–541PubMedPubMedCentralCrossRef Gladue H, Altorok N, Townsend W, McLaughlin V, Khanna D (2014) Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 43:536–541PubMedPubMedCentralCrossRef
28.
go back to reference Humbert M, Yaici A, de Groote P et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:3522–3530PubMedCrossRef Humbert M, Yaici A, de Groote P et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:3522–3530PubMedCrossRef
29.
go back to reference Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 40:441–445PubMedCrossRef Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum 40:441–445PubMedCrossRef
30.
go back to reference Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255PubMedCrossRef Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255PubMedCrossRef
31.
go back to reference Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L (2004) Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 43:1129–1137PubMedCrossRef Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L (2004) Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 43:1129–1137PubMedCrossRef
32.
go back to reference Alamanos Y, Tsifetaki N, Voulgari PV et al (2005) Epidemiology of systemic sclerosis in Northwest Greece 1981–2002. Semin Arthritis Rheum 34:714–720PubMedCrossRef Alamanos Y, Tsifetaki N, Voulgari PV et al (2005) Epidemiology of systemic sclerosis in Northwest Greece 1981–2002. Semin Arthritis Rheum 34:714–720PubMedCrossRef
33.
go back to reference Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 61:400–404PubMedCrossRef Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE (2009) Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 61:400–404PubMedCrossRef
34.
go back to reference Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F (2011) Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol 29(2 Suppl 65):S10–S14PubMed Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F (2011) Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol 29(2 Suppl 65):S10–S14PubMed
35.
go back to reference Airò P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M (2007) Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 25:878–880PubMed Airò P, Tabaglio E, Frassi M, Scarsi M, Danieli E, Rossi M (2007) Prevalence of systemic sclerosis in Valtrompia in northern Italy. A collaborative study of rheumatologists and general practitioners. Clin Exp Rheumatol 25:878–880PubMed
36.
go back to reference Valesini Litta A, Ms Bonavita et al (1993) Geographic clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 11:41–47PubMed Valesini Litta A, Ms Bonavita et al (1993) Geographic clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 11:41–47PubMed
Metadata
Title
Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012
Authors
Matteo Piga
Laura Casula
Silvia Sanna
Daniela Perra
Alberto Floris
Antonello Antonelli
Alberto Cauli
Alessandro Mathieu
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3330-1

Other articles of this Issue 1/2016

Rheumatology International 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.